

Capstone Therapeutics Corp.  
Form 8-K  
September 02, 2014

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT  
Pursuant to Section 13 OR 15(d) of  
The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported) **September 2, 2014**

**CAPSTONE THERAPEUTICS CORP.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**000-21214**  
(Commission File Number)

**86-0585310**  
(IRS Employer  
Identification No.)

**1275 West Washington Street, Suite 104, Tempe, Arizona**  
(Address of principal executive offices)

**85281**  
(Zip Code)

**(602) 286-5520**

Registrant's telephone number, including area code

---

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

**Section 1 - Registrant's Business and Operations**

**Item 1.02. Termination of a Material Definitive Agreement.**

On September 2, 2014, Capstone Therapeutics Corp. (the "Company") issued a press release announcing that it is ceasing further activity related to its former primary drug candidate, AZX100, and effective October 31, 2014, it is terminating the Amended and Restated License Agreement with Arizona Science and Technology Enterprises, LLC ("AzTE") (Licensor) dated February 23, 2006, and returning all interest in and rights to AZX100 intellectual property to AzTE.

**Section 7 - Regulation FD**

**Item 7.01. Regulation FD Disclosure.**

On September 2, 2014, the Company issued a press release on the results of an AEM-28 Phase 1a human clinical trial in cholesterol and lipid reduction conducted in Australia, by LipimetiX Development, LLC, the Company's joint venture affiliate. A copy of the press release is furnished hereto as Exhibit 99.1 and is incorporated by reference.

The information in this Item 7.01, including the accompanying exhibit, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section. The information in this Item 7.01 shall not be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language contained in such filing.

**Section 9 - Financial Statements and Exhibits**

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press Release dated September 2, 2014

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**CAPSTONE THERAPEUTICS CORP.**

Date: September 2, 2014

/s/ JOHN M. HOLLIMAN, III  
John M. Holliman, III  
*Executive Chairman*